Ítem
Acceso Abierto

Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases

Mostrar el registro sencillo de la publicación
dc.creatorAnaya, Juan-Manuelspa
dc.creatorDesanvicente-Celisspa
dc.creatorCaro-Morenospa
dc.creatorEnciso-Zuluagaspa
dc.date.accessioned2020-08-06T16:21:35Z
dc.date.available2020-08-06T16:21:35Z
dc.date.created2013-01spa
dc.description.abstractBiotherapeutic products have revolutionized medicine, changing the way we can treat some chronic diseases, such as autoimmune diseases. The patent expiry and the high costs of reference biotherapeutic products, among other factors, have promoted interest in similar biotherapeutic products (SBPs), also known as biosimilars. The objective of developing an SBP is to manufacture a “highly similar” molecule to a reference biotherapeutic product, by conducting a comparability exercise that can demonstrate similar quality, safety, and efficacy. Regulations like those of the World Health Organization, the European Medicines Agency, and the Food and Drug Administration are international reference standards. Herein, we aim to point out the current status in Latin America on SBPs, focusing on regulatory issues within the context of autoimmune diseases. The regulations of Argentina, Peru, Chile, Guatemala, Panama and Costa Rica follow the World Health Organization guidelines. Other countries, such as Cuba, Mexico, Venezuela, and Brazil have regulations that take into account international standards combined with local features. In Colombia, a draft decree is under revision and the debate is ongoing. Some countries have already approved SBPs. Mexico, Chile, Ecuador, Bolivia, and Peru market SBPs of rituximab, and Colombia markets an SBP of etanercept. The advent of SBPs is definitely beneficial. Safety and efficacy must be ensured following clear and comprehensive regulations.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.2147/bs.s38572
dc.identifier.issnISSN: 2230-245X
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/26401
dc.language.isoengspa
dc.publisherDovepress open access to scientific and medical researchspa
dc.relation.citationEndPage17
dc.relation.citationStartPage1
dc.relation.citationTitleBiosimilars
dc.relation.citationVolumeVol. 3
dc.relation.ispartofBiosimilars, ISSN: 2230-245X, Vol.3 (2013-01); pp.1-17spa
dc.relation.urihttps://www.dovepress.com/getfile.php?fileID=14840spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.sourceBiosimilarsspa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subject.keywordBiological therapyspa
dc.subject.keywordBiotechnologyspa
dc.subject.keywordSimilar biotherapeutic productspa
dc.subject.keywordAutoimmune diseasespa
dc.subject.keywordLatin Americaspa
dc.titleSimilar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseasesspa
dc.title.TranslatedTitleProductos bioterapéuticos similares en América Latina. Regulación y oportunidades para pacientes con enfermedades autoinmunesspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
BS-38572-similar-biotherapeutic-products-an-overview-from-latin-amer_010313.pdf
Tamaño:
947.35 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos